PerELISA: de-escalated therapy for HR+/HER2+ BC with Ki67 response following 2-week letrozole

PerELISA: de-escalated therapy for HR+/HER2+ BC with Ki67 response following 2-week letrozole

PerELISA: overexpression of 13 genes associated with endocrine sensitivity in HR+/HER2+ BCПодробнее

PerELISA: overexpression of 13 genes associated with endocrine sensitivity in HR+/HER2+ BC

Breast Cancer Survivor: Do THIS for Hormone Therapy Joint Pain ReliefПодробнее

Breast Cancer Survivor: Do THIS for Hormone Therapy Joint Pain Relief

Treatment de-escalation in premenopausal patients with HR+/HER2- breast cancer and micro-metastasisПодробнее

Treatment de-escalation in premenopausal patients with HR+/HER2- breast cancer and micro-metastasis

WSG TP-II trial: survival outcomes of de-escalated treatments in HER2+ breast cancerПодробнее

WSG TP-II trial: survival outcomes of de-escalated treatments in HER2+ breast cancer

ADAPT: de-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel in HR-/HER2+ eBCПодробнее

ADAPT: de-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel in HR-/HER2+ eBC

HRD, RB-loss gene sig, intrinsic subtype and response to neoadjuvant treatment in HR+/HER2- early BCПодробнее

HRD, RB-loss gene sig, intrinsic subtype and response to neoadjuvant treatment in HR+/HER2- early BC

Ki-67 index after neoadjuvant ET as a prognostic biomarker for HR+/HER2- early breast cancerПодробнее

Ki-67 index after neoadjuvant ET as a prognostic biomarker for HR+/HER2- early breast cancer

Treatment de-escalation and escalation strategies in HER2-positive breast cancerПодробнее

Treatment de-escalation and escalation strategies in HER2-positive breast cancer

Characterizing the immune microenvironment before and following anti-HER2 neoadjuvant therapyПодробнее

Characterizing the immune microenvironment before and following anti-HER2 neoadjuvant therapy

Comment: LUMINA results show that women with low levels of the Ki67 biomarker can avoid outcomes...Подробнее

Comment: LUMINA results show that women with low levels of the Ki67 biomarker can avoid outcomes...

Breast Cancer Survivor: Do THIS for Hormone Therapy Joint Pain ReliefПодробнее

Breast Cancer Survivor: Do THIS for Hormone Therapy Joint Pain Relief

The use of the Ki-67 in deciding which patients with HR+ breast cancer can safely avoid chemotherapyПодробнее

The use of the Ki-67 in deciding which patients with HR+ breast cancer can safely avoid chemotherapy

Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HE...Подробнее

Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HE...

Dual HER2 blockade in patients with HER2-positive breast cancer after pCRПодробнее

Dual HER2 blockade in patients with HER2-positive breast cancer after pCR

Cancer Secrets!Подробнее

Cancer Secrets!

MONALEESA-2: improved OS seen in HR+ advanced breast cancer treated with ribociclib + letrozoleПодробнее

MONALEESA-2: improved OS seen in HR+ advanced breast cancer treated with ribociclib + letrozole

The latest news on the management of breast cancer patients with brain metastasesПодробнее

The latest news on the management of breast cancer patients with brain metastases

De-escalation and escalation strategies for HER2+ breast cancerПодробнее

De-escalation and escalation strategies for HER2+ breast cancer